Anebulo Pharmaceuticals, Inc. – NASDAQ:ANEB

Add to watchlist

$2.61

+0.90

+53.53%

Market closed

Open in about 8 hours

-31.17%

month

-31.17%

quarter

-30.61%

year

Market Cap	25.93M
Enterprise value	N/A

P/E	-6.27
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	4.55
PEG ratio	-0.06
EPS	-0.37

Revenue	N/A
EBITDA	-9.34M
Income	-9.19M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Profit margin
Jun 2022	0	-2.31M
Mar 2023	0	-2.73M
Jun 2023	0	-2.49M
Mar 2024	0	-1.65M

Anebulo Pharmaceuticals Financials Estimate

Q Y

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Analyst Estimates
2028	78.75M	15.79M	20.06%

Analysts Price target
Financials & Ratios estimates

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Debt to assets
Dec 2022	16888256	1.37M	8.13%
Mar 2023	14432606	1.49M	10.33%
Jun 2023	11670151	1.06M	9.16%
Mar 2024	5995635	1.01M	16.85%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Cash Flow
Jun 2022	-1.99M	0
Mar 2023	-2.19M	0
Jun 2023	-2.84M	-68.15K
Mar 2024	-1.49M	0

Anebulo Pharmaceuticals alternative data

Anebulo Pharmaceuticals
Employees

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Employee count
Aug 2023	4
Sep 2023	4
Oct 2023	2
Nov 2023	2
Dec 2023	2
Jan 2024	2
Feb 2024	2
Mar 2024	2
Apr 2024	2
May 2024	2
Jun 2024	2
Jul 2024	2

Anebulo Pharmaceuticals
Hedge Funds Holdings Q1 2023

2.94% -27.25%

of ANEB is owned by hedge funds

4 -8

hedge funds hold ANEB stock

686.02K -6.36M

shares is hold by hedge funds

ANEB hedge funds holdings changes

Anebulo Pharmaceuticals
Insider Trading

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB): Insider trades (number of shares)
Period	Buy	Sel
Dec 2021	19148	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	17 Dec 2021	ENGLISH ARON R. other: See Explanation of Responses other: See Explanation of Respo..	Common Stock, par value $0.001 per share	400	$6.59	$2,634
Purchase	14 Dec 2021	ENGLISH ARON R. other: See Explanation of Responses other: See Explanation of Respo..	Common Stock, par value $0.001 per share	412	$5.9	$2,429
Purchase	3 Dec 2021	ENGLISH ARON R. other: See Explanation of Responses other: See Explanation of Respo..	Common Stock, par value $0.001 per share	4,500	$5.93	$26,685
Purchase	2 Dec 2021	ENGLISH ARON R. other: See Explanation Response other: See Explanation Response	Common Stock, par value $0.001 per share	13,836	$5.3	$73,331

ANEB insider trading transactions

Anebulo Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Rex Merchant CFA (1960) Chief Financial Officer	65	$239,580
Dr. Daniel Schneeberger M.B.A., M.D. (1984) Chief Executive Officer & Director	41	$13,980
Dr. Joseph F. Lawler M.D., Ph.D. (1972) Founder & Chairman	53	$5,500

Anebulo Pharmaceuticals
Latest News

Wednesday, 25 September 2024
16:05	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates	businesswire.com
Wednesday, 15 May 2024
13:15	Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development	businesswire.com
13:05	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates	businesswire.com
Tuesday, 13 February 2024
16:05	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates	businesswire.com
Tuesday, 14 November 2023
16:05	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates	businesswire.com
Thursday, 19 October 2023
11:21	Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?	Zacks Investment Research
Tuesday, 22 August 2023
11:17	Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001	Zacks Investment Research
Monday, 12 June 2023
10:43	Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?	Zacks Investment Research
Wednesday, 24 May 2023
10:42	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?	Zacks Investment Research
Friday, 27 January 2023
15:49	Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear	Seeking Alpha
Tuesday, 5 July 2022
08:00	Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants	Benzinga
Thursday, 23 June 2022
16:00	Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022	Business Wire
Friday, 11 February 2022
09:13	Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication	Benzinga
Monday, 18 October 2021
13:42	8 of the Hottest Cannabis Stocks Right Now	Schaeffers Research
Tuesday, 12 October 2021
08:59	Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem	Benzinga

Ideas & Opinions

Seeking Alpha 27 Jan 2023

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Frequently Asked Questions (FAQ)

What's the price of Anebulo Pharmaceuticals stock today?

One share of Anebulo Pharmaceuticals stock can currently be purchased for approximately $2.61.
When is Anebulo Pharmaceuticals's next earnings date?

Unfortunately, Anebulo Pharmaceuticals's (ANEB) next earnings date is currently unknown.
Does Anebulo Pharmaceuticals pay dividends?

No, Anebulo Pharmaceuticals does not pay dividends.
How much money does Anebulo Pharmaceuticals make?

Anebulo Pharmaceuticals has a market capitalization of 25.93M.
What is Anebulo Pharmaceuticals's stock symbol?

Anebulo Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ANEB".
What is Anebulo Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Anebulo Pharmaceuticals?

Shares of Anebulo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Anebulo Pharmaceuticals's key executives?
Anebulo Pharmaceuticals's management team includes the following people:
- Mr. Rex Merchant CFA Chief Financial Officer(age: 65, pay: $239,580)
- Dr. Daniel Schneeberger M.B.A., M.D. Chief Executive Officer & Director(age: 41, pay: $13,980)
- Dr. Joseph F. Lawler M.D., Ph.D. Founder & Chairman(age: 53, pay: $5,500)
Is Anebulo Pharmaceuticals founder-led company?

Yes, Anebulo Pharmaceuticals is a company led by its founder Dr. Joseph F. Lawler M.D., Ph.D..
How many employees does Anebulo Pharmaceuticals have?

As Jul 2024, Anebulo Pharmaceuticals employs 2 workers.
When Anebulo Pharmaceuticals went public?

Anebulo Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 7 May 2021.
What is Anebulo Pharmaceuticals's official website?

The official website for Anebulo Pharmaceuticals is anebulo.com.
Where are Anebulo Pharmaceuticals's headquarters?

Anebulo Pharmaceuticals is headquartered at 1415 Ranch Road 620 South, Lakeway, TX.
How can i contact Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals's mailing address is 1415 Ranch Road 620 South, Lakeway, TX and company can be reached via phone at +51 25980931.

Anebulo Pharmaceuticals, Inc.

anebulo.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

+51 25980931

1415 Ranch Road 620 South
Lakeway, TX 78734

CIK: 0001815974
ISIN: US0345691036
CUSIP: 034569103